Currently, Galmed Pharmaceuticals Ltd’s (GLMD) stock is trading at $0.30, marking a fall of -30.92% from last night’s close. At this price, the stock is -97.88% below its 52-week high of $14.18 and -14.41% above its 52-week low of $0.35. Based on the past 30-day period, the stock price is -39.88% below the high and +7.69% above the low.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, GLMD’s SMA-200 is $3.2748.
GLMD’s price to book ratio for the most recent quarter was 0.05, resulting in an 0.12 price to cash per share for the period.
How does Galmed Pharmaceuticals Ltd (GLMD) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 1 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 5.00 in simple terms.
Galmed Pharmaceuticals Ltd (GLMD): Earnings History
If we examine Galmed Pharmaceuticals Ltd’s recent earnings history, in the last quarter ended on 6/29/2023, it posted adjusted earnings per share of -$0.95, beating the consensus of -$0.34. In other words, it beat the consensus by -$0.61, resulting in a -179.40% surprise. In the 3 months period before the previous quarter which was closed on 6/29/2023, the stock recorded adjusted earnings per share of -$0.95 in contrast with the Outlook of -$0.34. That was a difference of -$0.61 and a surprise of -179.40%.
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Ownership Details
I will give a breakdown of the key shareholders in Galmed Pharmaceuticals Ltd (GLMD). Recent figures show that the company’s insiders hold 11.28% of shares. A total of 19 institutional investors hold shares in the company, making 15.26% of its stock and 17.20% of its float.
Sep 29, 2023, it was reported that the Company’s largest institutional holder is CVI Holdings, LLC holding total of 0.25 million shares that make 0.99% of the company’s total number of shares and are currently priced at 75837.0.
The securities firm Walleye Capital LLC holds 0.25 million shares of GLMD, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.99%, and the holding percentage of shares is valued at 75952.0.
An overview of Galmed Pharmaceuticals Ltd’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Galmed Pharmaceuticals Ltd (GLMD) traded 226,580 shares per day, with a moving average of $0.3890 and price change of -0.0900. With the moving average of $0.4713 and a price change of -0.5200, about 160,718 shares changed hands on average over the past 50 days. Finally, GLMD’s 100-day average volume is 256,172 shares, alongside a moving average of $0.8483 and a price change of -2.7100.
